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Abstract
Brain-derived neurotrophic factor (BDNF) plays crucial roles in brain function. Numerous studies report alterations in
BDNF levels in human serum in various neurological conditions, including mood disorders such as depression.
However, little is known about BDNF levels in the blood during pregnancy. We asked whether maternal depression
and/or anxiety during pregnancy were associated with altered serum BDNF levels in mothers (n= 251) and their new-
born infants (n= 212). As prenatal exposure to maternal mood disorders significantly increases the risk of neurological
conditions in later life, we also examined the possibility of placental BDNF transfer by developing a new mouse model.
We found no association between maternal symptoms of depression and either maternal or infant cord blood serum
BDNF. However, maternal symptoms of anxiety correlated with significantly raised maternal serum BDNF exclusively in
mothers of boys (r= 0.281; P= 0.005; n= 99). Serum BDNF was significantly lower in male infants than female infants
but neither correlated with maternal anxiety symptoms. Consistent with this observation, we found no evidence for
BDNF transfer across the placenta. We conclude that the placenta protects the developing fetus from maternal
changes in serum BDNF that could otherwise have adverse consequences for fetal development.
Introduction
Perinatal mental health problems impact nearly one-
quarter of all pregnancies1. In the UK alone, this costs
society > £8 billion for each year of births1 due to the risk
of substantial morbidity to mother and child2 and nega-
tive outcomes for the child3–5. Despite the considerable
clinical and financial burden to society, the biological
mechanisms linking maternal mood disorders to adverse
outcomes are unknown.
One mechanism potentially accounting for the pro-
gramming of disease risk is passage across the placenta of
maternal factors impacting fetal development during
sensitive periods, as has been suggested for the stress
hormone cortisol3,6. Brain-derived neurotrophic factor
(BDNF) is a member of the nerve growth factor family
expressed in the central and peripheral nervous system
with a key role in the development and function of neu-
rons7. In primates, but not mice, significant levels of
BDNF are detected in circulating blood platelets8, origi-
nating from megakaryocytes (MKs)9. Decreased serum
BDNF has been reported in numerous conditions,
including depression10–15, Huntington’s16 and Alzhei-
mer’s disease17, whilst increased BDNF has been asso-
ciated with autism spectrum disorder18. Circulating
BDNF is also known to fluctuate with exercise19.
Pregnancy is a unique state where the blood systems of
two individuals, the mother and the fetus, are intimately
associated but not in direct contact. In humans, there is a
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barrier between the maternal and fetal circulations com-
posed of a single continuous layer of syncytiotrophoblast
over a layer of villous cytotrophoblast covering the
endothelial cell-lined fetal blood vessels20. Despite sig-
nificant morphological differences, rodents also possess
the same hemochorial arrangement21, with the barrier
consisting of a discontinuous layer of sinusoidal tropho-
blast giant cells and two continuous layers of syncytio-
trophoblast covering fetal blood vessels22. Thus, in both
cases, there are three cellular layers between maternal and
fetal blood. Most proteins are too large to cross the pla-
centa. One exception is maternal antibodies which cross
the human syncytiotrophoblast by receptor-mediated
pinocytosis, an active process requiring the neonatal Fc
receptor23, and we note that a previous study in mice
concluded that maternal BDNF may be another protein
that can cross the placenta24.
Fluctuations in maternal serum BDNF may conse-
quently adversely influence fetal development. A small
number of studies have reported on maternal or fetal
serum BDNF levels (see Supplementary Table 125–46).
Lower maternal BDNF has been associated with postnatal
depression symptoms46 and lower cord blood BDNF
associated with major depression in pregnancy39 but
other studies report no association33,37. Two studies
reported a relationship between cord blood serum BDNF
and maternal anxiety symptoms, again with contrasting
findings33,42. To date, no study has reported on the status
of BDNF in blood from paired maternal and fetal samples
in relation to maternal symptoms of both depression and
anxiety.
In this study, we quantified BDNF levels in maternal
serum and matched cord blood serum in relation to
maternally reported symptoms of depression and anxiety,
generated as part of the Grown in Wales study47. Mouse
models have been extensively used to understand the
function of brain-derived BDNF48; however, BDNF is not
detectable in mouse MKs9 or blood49. Consequently, we
genetically engineered BDNF expression from MKs to
determine the potential for MK-derived maternal BDNF
transfer across the placenta near term.
Methods
Grown in Wales study
GiW study is a longitudinal pregnancy cohort study.
Women aged 18–45 with a singleton, term pregnancy
without fetal abnormalities or infectious diseases were
recruited at pre-surgical appointments prior to an
elective caesarean section (ELCS) at the University
Hospital of Wales. In total, 355 women provided
written consent; 7 women subsequently withdrew.
Perceived depression symptoms were assessed at
recruitment using the Edinburgh Postnatal Depression
Scale (EPDS)50 and trait anxiety by form Y-2 on the
Spielberger State-Trait Anxiety Inventory (STAI)
test51. Maternal venous serum samples were obtained
at recruitment and 1–4 days later cord venous blood
taken within 2 h of delivery. Blood was collected into
Vacutainer blood collection tubes (BD Biosciences,
367837), inverted several times and incubated at room
temperature (RT) for 1–2 h. After centrifugation at
3000 × g for 10 min at 4 °C, serum aliquots were stored
at −80 °C. Prior to data analysis, samples were exclu-
ded based on the following pre-established sample
exclusion criteria: women who went into natural labor
prior to their planned ELCS were included in the
analyses of maternal serum but their cord blood serum
samples were excluded; 36 samples from <36 weeks25
and non-Caucasian52 pairs were also excluded.
Serum BDNF ELISA
ELISA measurements of human serum were per-
formed blind to all participant information except
participant ID and type (maternal versus fetal), and as
described53, with minor changes. Briefly, NeutrAvidin-
coated plates (ThermoFisher Scientific, 15509) were
washed with Buffer A (0.1% TritonX-100 in 0.1 M
phosphate buffer: 0.1 M KH2PO4, 0.1 M Na2HPO4, pH
7.6) before incubating with 13 µg/ml biotin-BDNF-
Ab#154 for 2 h at RT. Plates were then washed with
Buffer B (Buffer A with 1% BSA), before the addition of
150 µl Buffer A. Next, 50 µl of either sample (1:20
dilution in Buffer B) or standard (in Buffer B) was added
and incubated for 6 h at RT while shaking. Following
Buffer A washes, 1.25 µg/ml HRP-BDNF-Ab#954 (in
Buffer B) was added for 3 h at RT, again shaking. After
further Buffer A washes, the chemiluminescent sub-
strate (Roche, 11582950001) was added and signal
detected by a microplate reader (FLUOstar OMEGA,
BMG Labtech). All plates contained two repeated
samples, and samples were analyzed in triplicate. ELISA
measurements of mouse serum were performed as
above, with the exceptions that experimenters were not
blinded to sample information, and the sample incu-
bation step was reduced to 3 h.
Western blot analysis
Western blots were performed as described53. Proteins
from 1 µl serum were separated on 4–12% Bis-Tris gra-
dient gels (Invitrogen, NP0321BOX) and transferred to
nitrocellulose membranes. After blocking for 1 h in 3%
BSA (Sigma-Aldrich, A7906), 3% ECL Prime Blocking
reagent (GE Healthcare) in TBS-T, membranes were
incubated overnight with anti-BDNF 3C11 antibody
(1:2000, Icosagen, 327-100). After washing, 1 h incubation
with HRP-conjugated goat anti-mouse IgG1 (1:2000,
Invitrogen, PA1-74421) followed, and membranes washed
and developed.
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Generation of Rosa26-LSL-BDNF-myc-IG mice
The pZDonor-Mouse-Rosa26 plasmid (Sigma-Aldrich,
D9196) was used as the backbone of a Rosa26 targeting
vector. We inserted a 4185 bp PCR fragment, containing
chimeric intron–exon-loxP-NeopA-loxP-MCS-IRES-eGFP-
pA amplified from the pCAGfloxNeoIRESeGFP plasmid
(gift from Professor Meng Li, Cardiff University) as a tem-
plate, to the EcoRI/XmaI site to generate pZDR-LSL-IG. To
generate pZDR-LSL-BDNF-myc-IG, a fragment containing
the BDNF-myc coding sequence was isolated by double
digestion with EcoRI/SacI from pCMV-BDNF-myc (con-
structed by adding one myc-tag copy at the C-terminus of
WT mouse BDNF following the deletion of the last three
amino acids55) and inserted into the PmeI site of pZDR-
LSL-IG.
Mouse ES cells E14TG2a were cultured in gelatin-
coated flasks or Petri dishes in GMEM medium (Ther-
moFisher Scientific, 11710035) with LIF (homemade) and
10% FCS (Biosera, FB-1001/500). To generate Rosa26-
LSL-BDNF-myc-IG mouse ES cells, cells were transfected
with pZDR-LSL-BDNF-myc-IG and pCMV-RosaL6
ELDmut and pCMV-RosaR4 KKRmut (gifts from
Charles Gersbach, Addgene plasmid #37198 and
#3719956) in a 10:1:1 ratio. Transfection was performed in
Nucleofector solution P3 (Lonza, V4XP-3024) using 4D-
Nucleofector X Unit (Lonza, AAF-1002X), program CG-
104. 5′-homologous recombination was confirmed by
generation of a 2.2 kb PCR fragment using primer pair
(GTGGAGCCGTTCTGTGAGAC and GTCATAGCCG
AATAGCCTCTCCAC), 3′ homologous recombination
by a 1.3 kb PCR fragment using primer pair (TCGAG
CTGGACGGCGACGTAAAC and TTGGGGGAGGAG
ACATCCACCTGG).
Rosa26-LSL-BDNF-myc-IG mice (BDNF-myc here-
after) were generated by injection of Rosa26-LSL-BDNF-
myc-IG mouse ES cells into C57BL/6 blastocysts. Germ-
line transmission was genotyped by PCR as above. Sub-
sequent genotyping was conducted by PCR using two
primer pairs (Bdnf pair: GAACTACCCAATCG-
TATGTTCG and CTACAAGTCTTCTTCAGAAATAA
GCTT; Rosa26 pair: AAGGGAGCTGCAGTGGAGTA
and GTCCCTCCAATTTTACACC) to identify hetero-
zygotes (140 bp and 275 bp products), homozygotes
(140 bp), and wild-type animals (275 bp).
Generation of animals expressing transgene BDNF-myc in
platelets
Pf4-Cre mice57 (The Jackson Laboratory, 008535,
C57BL/6 background) were crossed with BDNF-myc
animals to generate het BDNF-myc::Pf4-Cre mice.
Homozygous BDNF-myc::Pf4-Cre mice were generated
by crossing homozygous BDNF-myc with homozygous
BDNF-myc::Pf4-Cre mice. Pf4-Cre genotyping was by the
production of a 420 bp Pf4-Cre product (primer pair
CCAAGTCCTACTGTTTCTCACTC and TGCACAGT
CAGCAGGTT) and an internal 302 bp (Y chromosome)




Mouse megakaryocytes (Mks) were differentiated from
bone marrow as described9. Briefly, bone marrow was
flushed from femurs and tibias with Hank’s balanced salt
solution containing 0.38% sodium citrate, 1 mM adeno-
sine, 2 mM theophylline, and 5% FBS. Dissociated cells
were cultured in Iscove’s modified Dulbecco’s medium
with L-glutamine, 25 mM HEPES, 5% FBS, 100 units/ml
penicillin, 100 μg/ml streptomycin, 25 ng/ml stem cell
factor and TPO. Mature Mks were purified on a 1.5–3%
BSA gradient and cultured in Cellgro stem cell growth
media (CellGenix) for up to 16 h. For immunocy-
tochemistry, Mks were cultured on 200 μg/ml human
fibrinogen-coated coverslips for 6 h, fixed for 30 min in
4% paraformaldehyde in PBS, and permeabilized for
15min with 0.5% TritonX-100 in PBS. Two male animals
at the age of nine weeks were used for each genotype
group, experimental replicates were biological.
Whole blood cell and platelet counts
Following dilution of 20 μl of blood with 30 μl acid-
citrate-dextrose (ACD) buffer (85 mM trisodium citrate,
65 mM citric acid, 100mM glucose, pH 5.0) and 50 μl
PBS, 1 μl PE Rat Anti-Mouse CD41 (BD Pharmingen,
#561850) antibody was added to stain the platelets, and
incubated at RT for 30min. To this, 900 μl of fixative
(0.2% formyl saline) was added and incubated for a further
10min at RT. Finally, 10 μl of this fixed cell suspension
was then added to 990 μl PBS. A hemocytometer was used
to count whole blood cells using transmitted light, and
platelets counted using blue epifluorescence. Four animals
at the age of four months and of mixed sex were used for
each genotype group, experimental replicates were
biological.
FACS analysis of platelets and leukocytes
Blood was collected by cardiac puncture into 100 μl
ACD buffer and mixed with 1ml DMEM with 10%
heparin. To this, 8 ml Erythrocyte-Lysis-Buffer (10 mM
KHCO3, 155 mM NH4Cl, 0.1 mM EDTA, pH 7.5) was
added before 15min incubation on ice. Next, 5 ml PBS/
0.5% BSA was added, before centrifugation for 10 min at
200 × g at 4 °C, with the resulting cell pellet resuspended
in 1ml PBS/0.5% BSA. In all, 200 μl of cell suspension was
used for immunostaining (20min on ice) to examine
immune cell subpopulations (all antibodies from BD
Pharmingen, 1:400 dilutions). The cell suspension was
washed with 1ml PBS/0.5% BSA and centrifuged at 600×
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g for 6 min at 4 °C. To detect all immune cells as well as
the myeloid fraction, APC-conjugated anti-CD11b
(#561690) and APC-conjugated anti-CD45 (#561018)
were used. T and B cells were identified by PE anti-CD4
(#557308), PerCP anti-CD8a (#561092), and APC anti-
CD19 (#561738) antibodies. Prior to measurement, the
cell pellet was resuspended in 300 μl PBS/0.5% BSA, and
DAPI was used to exclude dead cells.
To stain platelets, 30 µl ACD/PBS (1:10) with PE rat
anti-mouse CD41 (#561850) or PE rat IgG1 control
(#551979) antibodies were added to 20 μl blood and
incubated for 30min at RT. 1 ml 0.2% formyl saline and
DAPI was then added before FACS analysis. PE rat IgG1
isotype controls were used for gating. For analysis,
doublets were gated out on DAPI-negative events. Two
female animals at the age of 4 months were used for each
genotype group, experimental replicates were biological.
Platelet isolation
Blood was collected by cardiac puncture into 100 μl
ACD buffer. Blood cells were removed by centrifugation
at 200 × g for 5 min at RT without brake and platelet-rich
plasma (PRP) collected. After centrifugation at 200 × g for
5 min at RT without brake to remove residual blood cells,
the further cleared PRP was collected and centrifuged at
900 × g for 10 min at RT without brake. Precipitated
platelets were resuspended in ACD and Ca2+-free Tyr-
odes buffer (134 mM NaCl, 2.9 mM KCl, 0.34 mM
Na2HPO4, 12 mM NaHCO3, 20 mM HEPES, 1 mM
MgCl2, 5 mM glucose) and centrifuged at 200 × g for
5 min at RT without brake. The further cleared PRP was
collected and centrifuged at 900 × g for 10 min at RT
without brake. The platelet pellet was then resuspended in
Ca2+-free Tyrode’s buffer for platelet spreading assays.
Platelet spreading assay
To stimulate activation, 2 mM CaCl2 and 0.01 U/ml
thrombin (Sigma-Aldrich) were added to 200 μl of rested
platelets, and platelets transferred immediately onto
fibrinogen-coated coverslips. Following incubation at
37 °C for 45min, attached platelets were fixed using 10%
neutral buffered formalin solution for 20min. After
washing with PBS/0.1% BSA, Alexa Fluor 555 Phalloidin
(1:1000 in PBS/0.1% BSA, ThermoFisher Scientific,
A34055) was used for staining. Activated platelets were
imaged by confocal microscopy (LSM 780, Zeiss), and
platelet sizes analyzed using ImageJ58. Two female ani-
mals at the age of four months were used for each gen-
otype group, experimental replicates were biological.
Mouse serum generation
BDNF-myc+/+;Cre+/− females were crossed with
BDNF-myc+/+;Cre−/− male mice to generate progeny
that were either BDNF-myc+/+;Cre+/− or BDNF-myc+/+;
Cre−/−. On 3 consecutive days, dams were sacrificed at
E18.5 and blood collected by cardiac puncture. Fetuses
were removed, before decapitation to collect blood. Blood
was incubated for 1 h at RT, followed by 1 h at 4 °C and
centrifugation at 2000 × g for 10 min at 4 °C; serum ali-
quots were stored at −80 °C. Three litters of fetuses were
analyzed at E18.5 with a total of 13 BDNF-myc+/+;Cre+/
−pups and 11 BDNF-myc+/+;Cre−/− fetuses, experi-
mental replicates were primarily biological. For adult
mice, blood was collected by cardiac puncture, and nine
Cre−/−, six BDNF-myc+/−;Cre+/−, and five BDNF-myc+/+;
Cre+/− animals, 2–3 months in age and of mixed sex
were analyzed by western blot. Data shown is repre-
sentative of four experiments, experimental replicates
were biological.
Statistics
RStudio V1.2.500159 was used for graphs and statistical
analysis (packages: “car”60, “dplyr”61, “ggplot2”62,
“ggpubr”63, “pastecs”64, and “reshape2”65). Median
(interquartile range (IQR)) are presented unless otherwise
stated. Normality was analyzed by Shapiro–Wilk test, and
variance by Levene’s test where appropriate. Group dif-
ferences were analyzed by Student’s t test (two-sided, with
unequal variance corrected for as a default parameter;
normally distributed data), Wilcoxon signed-rank test
(paired data), Wilcoxon rank test (non-paired data), or
linear modeling, and associations by Spearman’s rank
correlation or linear modeling. Confounding variables
controlled for in linear models of human serum values
were maternal hypertension66, gestational diabetes35,
maternal BMI at booking67, and smoking41, alcohol68,
strenuous exercise19, or antidepressant prescription10 at
any point during pregnancy, determined by previous lit-
erature. Analysis of human serum samples used samples
collected through the Grown in Wales study47. Although
this study was not designed to study serum BDNF, it was
considered to be sufficiently powered based on a previous
study on BDNF levels in human serum which indicated
that a cohort size of 60 was required to detect a 20%
difference between populations, and 200 for a 10% dif-
ference53. For analysis of mouse serum samples, no power
calculation was performed, as initial data fell into the
normal range. Randomization and blinding of mouse
samples were not performed, as groups were compared
across genotypes.
Study approval
Full ethical approval for the GiW Study cohort was
obtained from the Wales Research Ethics Committee REC
reference 15/WA/0004. The research was performed in
line with the principles of the Declaration of Helsinki as
revised in 2008. Mouse studies were approved by the
Cardiff University Ethical Review Board, and all
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experiments performed within the guidelines of the Home
Office Animals (Scientific Procedures) Act, 1986.
Results
Higher levels of maternal serum BDNF compared to fetal
BDNF
BDNF levels were measured in maternal and fetal serum
samples from the GiW cohort47. After filtering by the
sample exclusion criteria (“Methods”), BDNF levels were
measured by ELISA in 251 maternal and 212 fetal serum
samples (cohort demographics: Table 1).
BDNF values were not normally distributed in maternal
(Fig. 1A; P= 5.52e-05) or fetal (Fig. 1B; P= 1.77e-04)
serum. Values were significantly lower in fetal compared to
maternal circulation (Fig. 1C; median (IQR)— maternal:
15.15 (5.28); fetal: 9.6 (4.46) ng/ml; P < 2.20e−16 from 173
pairs, r=−0.575) and lower in male compared to female
cord blood (Fig. 1D; Supplementary Table 2), similar to
previous studies26,35,41,45. Fetal sex had no overall effect on
maternal serum BDNF values. Mothers with female infants
had serum BDNF levels of 15.47 ng/ml (4.88); male infants:
15.2 ng/ml (6.12). Analysis of the relationship between
individual maternal and fetal serum samples (Fig. 1E)
showed a moderate correlation (Spearman’s rank correla-
tion; r= 0.290, P= 1.09e−04, n= 173 pairs).
No association between BDNF and maternal EPDS scores
Maternal BDNF levels were not correlated with EPDS
scores reported at term when all samples were analyzed
(Fig. 2A; r=−0.022, P= 0.733, n= 244) or when samples
were analyzed by fetal sex (Fig. 2B; male infants: r= 0.06;
P= 0.522; n= 113. Female infants: r=−0.1; P= 0.258; n
= 131). There was no relationship between maternal
BDNF and categorically defined depression using the
EPDS ≥ 13 cutoff50 (Fig. 2C). There was also no associa-
tion between fetal BDNF and EPDS scores (Fig. 2D–F).
Significant association between maternal BDNF and
maternal STAI scores
Maternal BDNF levels were not correlated with STAI
scores when all samples were analyzed (Fig. 3A; r= 0.119;
P= 0.078; n= 220). However, when analyzed by fetal sex
STAI scores were significantly associated with maternal
serum BDNF in mothers of male (Fig. 3B; r= 0.281; P=
0.005; n= 99; Supplementary Table 3) but not female
infants (Fig. 3B; r=−0.014; P= 0.882; n= 121). When
analyzed categorically using STAI ≥ 40 suggesting anxi-
ety51, BDNF levels between groups were not significantly
different (Fig. 3C).
Fetal serum BDNF levels were not correlated with
maternal STAI scores when all data were analyzed (Fig.
3D; r= 0.056; P= 0.437; n= 192), or by fetal sex (Fig. 3E;
male: r= 0.131; P= 0.226; n= 87. Female: r= 0.073; P=
0.458; n= 105), or by group (Fig. 3F).
Table 1 Cohort demographic data.
Demographics Maternal: % (n)
or median (IQR)





33 (6) 0.223 33.5 (7) 0.020
Maternal BMI at
booking




Caucasian 100 (251) 100 (212)
Fetal sex, % (n) 0.498 2.02e-05
Female 54 (136) 54 (115)
Male 46 (115) 46 (97)
Parity, % (n) 0.218 0.374
Multiparous 81 (204) 79 (168)
Nulliparous 19 (47) 21 (44)
Gestational age
(weeks)
39 (0) 0.159 39 (0) 0.026
Smoking at any point
in pregnancy, % (n)
0.332 0.633
No 89 (224) 89 (189)
Yes 10 (24) 9 (20)
Missing 1 (3) 1 (3)
Alcohol at any point
in pregnancy, % (n)
0.819 0.330
No 58 (146) 60 (127)
Yes 40 (100) 38 (81)
Missing 2 (5) 2 (4)
Exercise, % (n) 0.48 0.502
No 81 (203) 82 (173)
Yes 18 (46) 17 (36)
Missing 1 (2) 1 (3)
Hypertension, % (n) 0.735 0.019
No 95 (239) 96 (203)
Yes 4 (9) 3 (7)




No 92 (232) 93 (198)
Yes 6 (14) 5 (10)




Left before GCSE 5 (13) 7 (14)
GCSE & vocational 22 (55) 20 (42)
A-level 12 (31) 11 (24)
University 29 (74) 30 (64)
Postgraduate 26 (66) 28 (60)
Missing 5 (12) 4 (8)
Family income, % (n) 0.064 0.154
<18,000 7 (18) 7 (14)
18–25,000 10 (24) 8 (16)
25–43,000 20 (49) 19 (41)
>43,000 51 (127) 51 (108)
Do not wish to say 10 (25) 12 (26)
Missing 3 (8) 3 (7)





No 91 (228) 93 (197)
Yes 9 (23) 7 (15)
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Maternal BDNF does not cross the placenta
To assess the potential for MK-derived BDNF to cross
the placenta, we exploited the fact that wild-type mice
do not have BDNF present in their blood69 and engi-
neered a novel mouse model in which BDNF was
expressed from MKs. We inserted a myc-tagged BDNF-
IRES-eGFP into the Rosa26 locus (Fig. 4A). When this
line is crossed to mice expressing PF4-Cre, driving Cre
expression specifically within MKs57, mice should
express BDNF from MKs (Fig. 4A) as in humans9.
Through breeding, we generated animals of the follow-
ing genotypes: BDNF-myc+/+;Cre+/− and BDNF-myc+/+;
Cre−/− (homozygous for the BDNF-myc allele, positive
or negative for expression of PF4-Cre), BDNF-myc+/−;
Cre+/− and BDNF-myc+/−;Cre−/− (heterozygous for
BDNF-myc, positive or negative for PF4-Cre) and lastly
BDNF-myc−/−;Cre+/− and BDNF-myc−/−;Cre−/− (wild-
type in the BDNF-myc allele, positive or negative for PF4-
Cre). All genotypes were viable and fertile, with no overt
phenotype. The hematological profile of mice carrying
one or two alleles of BDNF-myc and the Cre transgene
(BCre; recombined scenario) was similar to mice carrying
a BDNF-myc allele in the absence of the Cre transgene
(unrecombined) (B) (Fig. 4B, C). In animals carrying the
Cre transgene and one or two alleles of the BDNF-myc
(BCre: BDNF-myc+/+;Cre+/− or BDNF-myc+/−;Cre+/−),
BDNF could be detected in MKs (Fig. 4D). To reach the
bloodstream, MK-expressed BDNF must be packaged into
platelets, from which it can be released during platelet
activation. Activation-induced platelet spreading (Fig. 4E)
and platelet counts (Fig. 4F) were similar between BCre
and B mice. In animals without the Cre transgene (B),
~0.5% of white blood cells (0.52 ± 0.1% (SD)) were positive
for eGFP whereas over 85% of platelets from BCre mice
expressed eGFP (Fig. 4G). BDNF-myc was detectable by
western blot in the serum of BCre mice and not detectable
in mice without the Cre transgene (Fig. 4H and Supple-
mentary Fig. 1). By ELISA, the mean (± standard error of
the mean) serum BDNF values in young adult mice
(12 weeks old) were 10.6 ± 1.45 ng/ml in BDNF-myc+/−;
Cre+/− animals (n= 4; three female, one male), and
32.3 ± 3.70 ng/ml in BDNF-myc+/+;Cre+/− animals (n=
3; three female). Thus, in this model MK-derived BDNF is
present in serum at levels comparable to those deter-
mined in adult human serum53.
Having confirmed MK expression of BDNF, this model
was used to test if MK-derived BDNF in maternal blood
could cross the placenta. BDNF-myc+/+;Cre+/− females
expressing MK-derived BDNF were crossed with BDNF-
myc+/+;Cre−/− male mice to generate fetuses homozygous
for the BDNF-myc insertion, with approximately half
lacking the Cre transgene and thus intrinsic serum BDNF.
Cre-negative fetuses (BDNF-myc+/+;Cre−/−) could only
have serum BDNF if this were maternally-derived. Mater-
nal and fetal blood were collected at E18.5 from 3 litters,
serum generated and BDNF expression analyzed by wes-
tern blot. BDNF-myc was detectable in maternal serum
and serum from BDNF-myc+/+;Cre+/− fetuses but absent
in serum from the BDNF-myc+/+;Cre−/− fetuses (Fig. 4I).
Discussion
This is the first study to interrogate the relationship
between maternal and fetal serum BDNF at term in the
context of maternal symptoms of depression and anxi-
ety. We discovered that maternal symptoms of anxiety
correlated with significantly raised maternal serum
BDNF exclusively in mothers of boys. We did not find
similarly raised BDNF levels in the male infants, in line
with the results obtained with our new animal model in
which we found no evidence that MK-derived BDNF,
the main source of BDNF in humans, crosses the
placenta.
Elevated maternal BDNF was specifically associated
with maternally reported anxiety symptoms and not
symptoms of depression. Symptoms of depression have
been associated with lower serum BDNF in non-pregnant
adults10,11. Reports of associations between anxiety
symptoms and serum BDNF have been mixed, with one
systematic review concluding lower BDNF only in asso-
ciation with obsessive-compulsive disorder70. Animal
studies suggest that overexpression of BDNF in the brain
can simultaneously improve performance in tests related
to depression while facilitating anxiety-like behavior71.
This would be essentially consistent with our findings of a
contrasting relationship of serum BDNF with anxiety and
depressive symptoms. Testing the relationship between
MK-derived BDNF and behavioral outcomes will now be
possible using the animal model described here.
Our finding of elevated maternal BDNF was exclusive
to the mothers of boys reporting higher anxiety symp-
toms. We currently do not know whether this is a causal
relationship nor, if causal, the direction of causality.
Anxiety symptoms, or factors associated with anxiety,
may drive changes in maternal BDNF that are only per-
missible in those mothers with a male fetus. Alternatively,
Table 1 continued
Demographics Maternal: % (n)
or median (IQR)
P Fetal: % (n) or
median (IQR)
P
EPDS score 7 (6) 0.733 7 (6) 0.394
Missing, n 7 6
STAI score 33.5 (12) 0.078 33.5 (13) 0.437
Missing, n 31 20
EPDS Edinburgh Postnatal Depression Scale, STAI State-Trait Anxiety Inventory,
WIMD Welsh Index of Multiple Deprivation. For WIMD scores, please see gov.
wales/welsh-index-multiple-deprivation. Low scores indicate high deprivation,
whilst high scores indicate low levels of deprivation. P values indicate the
significance of the relationship between serum BDNF levels and the
corresponding variable. Bold values indicate P < 0.05.
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under conditions of maternal anxiety, the male fetus or
placenta may produce signals driving elevations in
maternal BDNF. A third possibility is that elevated BDNF
is causing anxiety only in mothers with boys. Subsequent
studies with our new mouse model should help tease
apart these complex relationships. In addition to
determining causality, it will also be important to estab-
lish whether changes in maternal BDNF occur as a result
of alterations in MK proliferation, MK differentiation,
BDNF expression within MKs, and/or platelet release of
BDNF into the circulation. Another important question





Fig. 1 Characterization of serum BDNF levels in maternal and fetal serum. Distribution of serum BDNF values in maternal A and fetal B samples.
C Comparison of serum BDNF values between matched maternal and fetal samples (Wilcoxon signed-rank test, P < 2.20e-16, r=−0.575, n= 173
maternal–fetal pairs). Gray lines connect maternal–fetal pairs. D Fetal serum BDNF comparison between female and male infant cord blood serum.
***P < 0.001 between female (n= 115) and male (n= 97) serum samples. After controlling for potential confounding variables (hypertension,
gestational diabetes, maternal BMI at booking, smoking, or alcohol at any point in pregnancy, strenuous exercise and prescription of antidepressants)
in a linear model, male fetal sex was associated with a decrease in serum BDNF of 2.20 ng/ml (95% confidence intervals (CI): −3.21, −1.19, P= 2.63e-
5) compared to females (median (IQR)—female: 10.45 (4.45); male: 8.53 (3.86) ng/ml). Boxplot values indicate the following: Box boundaries, 25% and
75% quartiles; mid-line, median; notch, 1.58 × interquartile range (IQR)/sqrt (n); whiskers, highest and lowest values within 1.5 × IQR of the box
boundary; outliers, values outside the whiskers. Unadjusted vs. adjusted model shown in Supplementary Table 2. E Relationship between paired
maternal and fetal serum BDNF levels (r= 0.290, P= 1.09e-04, n= 173 pairs, Spearman’s rank correlation; 95% confidence intervals are shaded in
gray). In a linear model analyzing this relationship whilst controlling for potential confounding variables (see “Methods”), a 1 ng/ml increase in
maternal serum BDNF corresponded to a 0.385 ng/ml increase in fetal serum BDNF (95% CI: 0.244, 0.526, P= 2.62e-07).
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development or disease. While further work is required,
our identification of this sex-specific association between
maternal anxiety and maternal serum BDNF provides a
highly novel example of the influence of fetal sex on the
maternal state.
Whether these perturbations in maternal serum BDNF
are transmitted to the fetus is an important question,
given the known critical function of BDNF in the central
nervous system and our increasing understanding of its
function in the periphery, including in energy homeostasis
and regulation of glucose levels72,73. We found no evi-
dence that BDNF can cross the placenta, at least in mice.
Maternal blood BDNF is contained within platelets and is
not found as free serum protein. Furthermore, the
hemochorial placenta provides a physical barrier with
three continuous cellular layers between the maternal and
fetal blood systems in both mice and humans22. Some
proteins can cross the placenta by an active process
termed receptor-mediated pinocytosis23. We were unable
to detect TrkB or p75 by western blot analysis of placental
extracts or by immunostaining in the labyrinth of the
mouse placenta where transport occurs (data not shown)
consistent with the lack of BDNF transplacental transfer
in our model. While we cannot formally exclude the
possibility that there are species differences in the pla-
cental transfer of BDNF as observed with the transfer of
maternal antibodies74, BDNF receptors do not appear to
be expressed in the mature human placenta75.
An important feature of our study is the number of
paired maternal:fetal BDNF samples measured at term.
However, we only measured mood symptoms once during





Fig. 2 No correlation between serum BDNF levels and maternally reported depression symptoms. A, B Maternal serum BDNF values plotted
against EPDS scores, using (A) the whole population (r=−0.022, P= 0.733, n= 244), and (B) split by fetal sex (female: r=−0.1, P= 0.258, n= 131;
male: r= 0.06, P= 0.522, n= 113, Spearman’s rank correlation). C Comparison of maternal serum BDNF values across depression categories and
separated by fetal sex (n: female infants, EPDS < 13: 112; ≥13: 19; male infants, EPDS < 13: 98; ≥13: 15). D, E Fetal serum BDNF values plotted against
EPDS scores, using (D) the whole population (r= 0.060, P= 0.394, n= 206), and (E) split by fetal sex (female: r= 0.13, P= 0.176, n= 111; male: r=
0.05, P= 0.660, n= 95, Spearman’s rank correlation). F Comparison of fetal serum BDNF values across depression categories and separated by fetal
sex (n: female infants, EPDS < 13: 94; ≥13: 17; male infants, EPDS < 13: 84; ≥13: 11). Note: fewer samples were available for the fetal serum analysis.
EPDS: Edinburgh postnatal depression score. 95% confidence intervals are shaded in gray. Boxplot values indicate the following: Box boundaries, 25%
and 75% quartiles; mid-line, median; whiskers, highest and lowest values within 1.5 × IQR of the box boundary; outliers, values outside the whiskers.
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manifested but the persistence of symptoms after birth47
and the nature of the questionnaire, measuring trait not
state anxiety, suggests prolonged symptomology. Our
cohort is relatively homogeneous and it will be important
to replicate these findings in more diverse cohorts, and
across other modes of delivery.
In summary, we have discovered a sex-specific asso-
ciation between maternally reported symptoms of anxiety
and elevated maternal serum BDNF at term, specifically in
pregnancies with male infants. We find no evidence that
maternal serum BDNF crosses the placenta either from
our human study or in our new humanized mouse model.
We conclude that the placenta provides a barrier
protecting the fetus against potentially damaging fluc-
tuations in maternal BDNF that occur under conditions of
stress.
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Fig. 4 Evidence that BDNF does not transfer across the placenta. A Schematic of the generation of the BCre mouse model expressing BDNF
from megakaryocytes. B Whole blood cell counts (including red blood cells and leukocytes) in BCre and B animals (t test: P= 0.377; n= 4 of each
genotype; mean ± SEM). C The composition of the major subtypes of leukocytes in BCre and B animals; n= 2 animals of each genotype.
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